Xenetic Biosciences plc, a publicly traded British drug company with a focus on developing treatments for rare diseases, plans to relocate its drug development operations to Massachusetts and hire up to six employees in the Bay State before the end of the year. The announcement was made jointly by the company, the office of Governor Deval Patrick, and the Massachusetts Life Sciences Center, a quasi-public agency of the Commonwealth. Xenetic Biosciences said it expects to have about 20 Massachusetts employees by the end of 2013, possibly in a facility in either Waltham or Lexington.
